Experts in Excipients - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Experts in Excipients

MEGGLE Excipients & Technology is a global leader in the manufacture of lactose for the pharmaceutical industry.  Supporting supply chain security with manufacturing facilities in Europe and North America, MEGGLE offers a broad product portfolio of lactose excipients, co-processed technologies and excipient contract manufacturing. 


MEGGLE is a pioneer in co-processing technologies that allow simple, robust formulation development and manufacture.  Through co-processing, MEGGLE developed highly functional excipients possessing unique qualities for directly compressible immediate and sustained release pharmaceutical solid dosage forms. 
As a family owned, German company, MEGGLE has proudly produced quality products for consumers and industry for four generations.

                MEGGLE Excipients & Technologies serves the pharmaceutical and biotechnology markets with a global network of offices and authorized agents. As an innovator in co-processed technology, MEGGLE also provides contract manufacturing services to several other global excipient companies.
Our broad portfolio of products, multiple manufacturing locations, technical centers in major markets, and innovative technologies, make MEGGLE the preferred supplier and valued partner by large and small pharmaceutical product manufacturers.      

MEGGLE Excipients & Technologies excipient products:

  • Lactose monohydrate
  • Anhydrous Lactose
  • Co-Processed Excipients
  • Lactose for Inhalation
  • Lactose for lyophilization and parenteral applications
  • Customized lactose products

MEGGLE Gruppe Wasserburg

Service.pharma@meggle.de
www.meggle-pharma.com
Phone +49 8071 73 476
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here